跳至主要内容
临床试验/NCT04910230
NCT04910230已完成不适用

Efficiency and Safety of Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19: A Randomized Clinical Trial

Qiang Hu1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2020年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
changes in absolute lymphocyte counts

研究概览

简要总结

The mechanism of peripheral blood lymphocyte decline in COVID-19 patients is not yet clear. However, one theory demonstrated that in the whole progression of COVID-19, the extensive activation of poly-ADP-ribose polymerase (PARP) may reduce the cellular NAD+ and dampen the adaptive immune system. So investigators presume that replenishing the NAD+ using nicotinamide as the precursor may improve the lymphocyte counts and boost the adaptive immune system. As a result, the study using nicotinamide as a kind of supportive therapy provide further evidence of their efficiency and safety in treating lymphopenia in patients with COVID-19.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • the patients diagnosed as the common or severe cases of COVID-19
  • aged 18-85
  • the absolute lymphocyte counts below the normal value (<1.1-3.2×109/L)

排除标准

  • the patients who are diagnosed as critically ill cases or participating in other clinical trials
  • women who are pregnant or lactating
  • ALT/AST > 5 times upper limit of normal (ULN), neutrophils counts < 0.5×109/L, platelets counts< 50×109/L
  • patients diagnosed with rheumatoid immune-related diseases
  • patients who take long-term oral anti-rejection drugs or immunomodulatory drugs
  • hypersensitive reaction to nicotinamide or any auxiliary materials
  • patients with active tuberculosis or combined with bacterial and fungal infections
  • patients undergoing organ transplant
  • patients with mental disorders.

研究组 & 干预措施

nicotinamide plus usual care

Experimental

干预措施: nicotinamide (Drug)

结局指标

主要结局

changes in absolute lymphocyte counts

时间窗: before and 48 hours after intervention

the changes in absolute lymphocyte counts (\*10\^9/L) in before and 48 hours after treatment

次要结局

  • the death in hospital(before and 48 hours after intervention)
  • the composite endpoint of aggravation(before and 48 hours after intervention)

研究者

发起方
Qiang Hu
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Qiang Hu

Principal Investigator

Shenyang Northern Hospital

研究点 (1)

Loading locations...

相似试验

Nicotinamide-based Supportive Therapy in Lymphopenia... | 临床试验